Recurring mutations found by sequencing an acute myeloid leukemia genome

New England Journal of Medicine

Volumn 361, Issue 11, 2009, Pages 1058-1066

  Mardis, Elaine R ^a,b   Ding, Li ^a,b   Dooling, David J ^b   Larson, David E ^b   McLellan, Michael D ^b   Chen, Ken ^b   Koboldt, Daniel C ^b   Fulton, Robert S ^b   Delehaunty, Kim D ^b   McGrath, Sean D ^b   Fulton, Lucinda A ^b   Locke, Devin P ^b   Magrini, Vincent J ^a,b   Abbott, Rachel M ^b   Vickery, Tammi L ^b   Reed, Jerry S ^b   Robinson, Jody S ^b   Wylie, Todd ^b   Smith, Scott M ^b   Carmichael, Lynn ^b   Eldred, James M ^b   Harris, Christopher C ^b   Walker, Jason ^b   Peck, Joshua B ^b   Du, Feiyu ^b   Dukes, Adam F ^b   Sanderson, Gabriel E ^b   Brummett, Anthony M ^b   Clark, Eric ^b   McMichael, Joshua F ^b   Meyer, Rick J ^b   Schindler, Jonathan K ^b   Pohl, Craig S ^b   Wallis, John W ^b   Shi, Xiaoqi ^b   Lin, Ling ^b   Schmidt, Heather ^b   Tang, Yuzhu ^b   Haipek, Carrie ^b   Wiechert, Madeline E ^b   Ivy, Jolynda V ^b   Kalicki, Joelle ^b   Elliott, Glendoria ^b   Ries, Rhonda E ^a   Payton, Jacqueline E ^a   Westervelt, Peter ^a,c   Tomasson, Michael H ^a,c   Watson, Mark A ^a,b,c   Baty, Jack ^a   Heath, Sharon ^a,c   Shannon, William D ^a,c   Nagarajan, Rakesh ^a,c   Link, Daniel C ^a,c   Walter, Matthew J ^a,c   Graubert, Timothy A ^a,c   DiPersio, John F ^a,c   Wilson, Richard K ^a,b,c   Ley, Timothy J ^a,b,c   more..

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ISOCITRATE DEHYDROGENASE 1; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CYTOGENETICS; DISEASE COURSE; DRUG MEGADOSE; GENE; GENE MUTATION; GENETIC CONSERVATION; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL;

EID: 70149093912     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0903840     Document Type: Article

References (30)

1. Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999;23:166-175
2. Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia - a review. Br J Haematol 2008;140:123-132 (Pubitemid 350265048)
3. Schlenk RF, Döohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-1918 (Pubitemid 351620111)
4. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-4336 (Pubitemid 35429670)
5. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-1320
6. Rücker FG, Bullinger L, Schwaenen C, et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 2006;24:3887-3894 (Pubitemid 46630736)
7. Suela J, Alvarez S, Cifuentes F, et al. DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups. Leukemia 2007;21:1224-1231 (Pubitemid 46831812)
8. Tyybäkinoja A, Elonen E, Piippo K, Porkka K, Knuutila S. Oligonucleotide array-CGH reveals cryptic gene copy number alterations in karyotypically normal acute myeloid leukemia. Leukemia 2007;21:571-574 (Pubitemid 46306576)
9. Walter MJ, Payton JE, Ries RE, et al. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A (in press).
10. Bullinger L, Döhner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004;350:1605-1616 (Pubitemid 38501163)
11. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004;350:1617-1628 (Pubitemid 38528701)
12. Baldus CD, Mrózek K, Marcucci G, Bloomfield CD. Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. Br J Haematol 2007;137:387-400. (Pubitemid 46698282)
13. Heuser M, Beutel G, Krauter J, et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 2006;108:3898-3905 (Pubitemid 44864574)
14. Langer C, Radmacher MD, Ruppert AS, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 2008;111:5371-5379
15. Lugthart S, van Drunen E, van Norden Y, et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 2008;111:4329-4337
16. Marcucci G, Maharry K, Whitman SP, et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2007;25:3337-3343 (Pubitemid 47325620)
17. Pratz K, Levis M. Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Leuk Lymphoma 2008;49:852-863 (Pubitemid 351942737)
18. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008;456:66-72.
19. Bentley DR, Balasubramanian S, Swerdlow HP, et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 2008;456:53-59
20. Li H, Ruan J, Durbin R. Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res 2008;18:1851-1858
21. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-266 [Erratum, N Engl J Med 2005;352:740.]
22. Bleeker FE, Lamba S, Leenstra S, et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009;30:7-11.
23. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-773
24. Kang MR, Kim MS, Oh JE, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 2009;125:353-355
25. Ng PC, Henikoff S. Accounting for human polymorphisms predicted to affect protein function. Genome Res 2002;12:436-446 (Pubitemid 34233019)
26. Link DC, Kunter G, Kasai Y, et al. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood 2007;110:1648-1655 (Pubitemid 47443983)
27. Sjöblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-274 (Pubitemid 44571966)
28. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009;324:261-265
29. Dulbecco R. A turning point in cancer research: sequencing the human genome. Science 1986;231:1055-1056
30. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009;458:719-724